VIRI: Virios Analyst Median Target

Virios Therapeutics (VIRI) focuses on developing therapies to combat chronic fatigue and fibromyalgia, leveraging the link between herpesviruses and pain. The business model is based on outsourcing drug development to third-party contractors, which reduces costs. The current metric stands at 1.00. This chart of the market price illustrates the price action of the asset, which is protected by patents but competes for investment with other biopharmaceutical startups.

VIRI: Virios Analyst Consensus Forecast 07/04/2022 - 10/09/2024

Analytical breakdowns for Virios Therapeutics (VIRI)

- current price and projected stock value:

Price Chart virios.com|VIRI - Analyst Consensus Forecast

- market capitalization information:

Market Capitalization Virios|VIRI - Total Company Value

- company book value details:

Accounting Value of a Share Virios Therapeutics|VIRI - Book Capitalization|Market Capitalization to Book Value virios.com|VIRI - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- earnings and valuation multiples information:

VIRI - Net Profit|Projected Future Earnings Virios Therapeutics|VIRI - Price to Earnings Ratio|Future Price to Earnings Multiple virios.com|VIRI - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Virios|VIRI - Operating profit EBITDA|Net earnings per share for the last four quarters Virios Therapeutics|VIRI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months virios.com|VIRI - Net earnings per share growth this year|Earnings growth forecast for next year Virios Therapeutics

General company analysis:VIRI Virios Therapeutics Inc.

Flagship merchandise of Virios Therapeutics, Inc.

Investors face a choice between current yield and the risk of underestimating the potential of Virios Therapeutics (VIRI). Analyzing the analyst consensus chart for the stock reveals the trend of target price revisions, where declines signal recessionary trends, while stability confirms the company's strong pricing power driven by inelastic demand for its unique therapy for viral CNS lesions.

Competitors of Virios Therapeutics